Department of Defense PRMRP Clinical Trial Grant for Rapid Implementation of Health Interventions

The FY22 PRMRP Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on a disease or condition addressed in one of the congressionally directed FY22 PRMRP Topic Areas and FY22 PRMRP Strategic Goals. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.

Funding from this award mechanism must support a clinical trial. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. For more information, a Human Subject Resource Document is provided at https://cdmrp.army.mil/pubs/pdf/Human%20Subjects%20Resource%20Document.pdf. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other FY22 PRMRP program announcements being offered. For information about these award mechanisms, see https://cdmrp.army.mil/funding/prmrp.